comprehensive -WSS

comprehensive

author：leisure time 2025-10-01 00:45:54 - browse：2515

Exact Sciences headquarters. -- biotech coverage from STAT — Exact Sciences' headquarters in Madison, Wis. Wikimedia Commons

Exact Sciences reported first-quarter revenues this week that beat market expectations, and the cancer detection company’s executives still believe they’re on track to meet expected 2024 revenue.

That’s usually good news. Yet Exact shares are down nearly 11% on Thursday, dipping to $53.12 within the first few hours of trading. During after-hours trading on Wednesday, shortly after Exact released its financial updates, shares tumbled as low as $47.24.

The seemingly paradoxical result reflects worries about a potential slowdown in future growth at Exact, a $10 billion biotech best known for Cologuard, a colon cancer screening test that detects blood and DNA from stool samples. The test, which first won regulatory approval in 2014, was designed to boost cancer screening rates by providing a more convenient alternative to colonoscopies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： The (many) problems with a new study criticizing cancer screening

WSS

Crinetics acromegaly drug succeeds in late

A new House health package & hospitals’ new site

Covid hospitalizations on the rise, Humana says

A rare thyroid diagnosis led to unexpected, all

Amazon on where the company's health care bets are headed next

Snackable artificial intelligence, expert AI, and the pharma industry

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Biotech companies concerned about China biosecurity crackdown

Continuity nursing helped my family in our darkest PICU moments

NIH nominee Bertagnolli will get October confirmation hearing

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

An inside look at PIPEs, biotech's buzzy new financing tool

Dobbs anniversary: the lost opportunity of abortion as health care

Humana sues Biden admin over Medicare Advantage audit rule

leisure time

Snackable artificial intelligence, expert AI, and the pharma industry

Covid hospitalizations on the rise, Humana says

House looks to weaken Medicare negotiation

What drug price negotiations mean for Medicare Part D

In search for therapies for solid tumors, companies turn to claudin

What American doctors can learn from their Israeli counterparts

entertainment

hotspot

entertainment

entertainment